Jennifer L Clarke

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Bevacizumab and other targeted agents in the upfront treatment of glioblastoma
    Jennifer L Clarke
    Department of Neurology, University of California, San Francisco, CA Department of Neurological Surgery, University of California, San Francisco, CA Electronic address
    Semin Radiat Oncol 24:273-8. 2014
  2. ncbi request reprint Leptomeningeal metastasis from systemic cancer
    Jennifer L Clarke
    University of California, San Francisco, 400 Parnassus Avenue, A 808, Box 0372, San Francisco, CA 94143, USA
    Continuum (Minneap Minn) 18:328-42. 2012
  3. ncbi request reprint Neuroimaging: diagnosis and response assessment in glioblastoma
    Jennifer L Clarke
    Department of Neurological Surgery, Division of Neuro Oncology, University of California San Francisco, San Francisco, CA 94143 0372, USA
    Cancer J 18:26-31. 2012
  4. ncbi request reprint Pseudoprogression and pseudoresponse: challenges in brain tumor imaging
    Jennifer L Clarke
    Department of Neurological Surgery, Division of Neuro Oncology, University of California San Francisco, 400 Parnassus Avenue, A 808, Box 0372, San Francisco, CA 94143, USA
    Curr Neurol Neurosci Rep 9:241-6. 2009
  5. pmc Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?
    Jennifer L Clarke
    Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Avenue, A 808, San Francisco, CA 94143 0372, USA
    Neuro Oncol 13:1118-24. 2011
  6. ncbi request reprint Recent advances in therapy for glioblastoma
    Jennifer Clarke
    Division of Neuro Oncology, Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Ave, Room A 808, Box 0372, San Francisco, CA 94143 0372, USA
    Arch Neurol 67:279-83. 2010
  7. pmc Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide
    Mei Yin C Polley
    Brain Tumor Research Center, Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, Room A 808, Box 0372, San Francisco, California 94143 2167, USA
    Neuro Oncol 12:274-82. 2010
  8. ncbi request reprint Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment
    Aaron J Clark
    Department of Neurological Surgery, University of California, San Francisco, San Francisco, California 94143 0112, USA
    Neurosurgery 70:361-70. 2012
  9. pmc Relationship of glioblastoma multiforme to the subventricular zone is associated with survival
    Nazia F Jafri
    Department of Radiology, University of California, San Francisco, San Francisco, California, USA
    Neuro Oncol 15:91-6. 2013
  10. pmc Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma
    Seunggu J Han
    Department of Neurological Surgery, University of California, San Francisco, California S J H, J D R, A M M, J L C, M D P, S M C, M S B, A D, N A B Department of Epidemiology and Biostatistics, University of California, San Francisco, California A M M
    Neuro Oncol 16:1255-62. 2014

Detail Information

Publications14

  1. ncbi request reprint Bevacizumab and other targeted agents in the upfront treatment of glioblastoma
    Jennifer L Clarke
    Department of Neurology, University of California, San Francisco, CA Department of Neurological Surgery, University of California, San Francisco, CA Electronic address
    Semin Radiat Oncol 24:273-8. 2014
    ..Results of recent studies of such agents are discussed. Although many of these agents show promise, none as yet has established a new standard of care for these difficult-to-treat tumors. ..
  2. ncbi request reprint Leptomeningeal metastasis from systemic cancer
    Jennifer L Clarke
    University of California, San Francisco, 400 Parnassus Avenue, A 808, Box 0372, San Francisco, CA 94143, USA
    Continuum (Minneap Minn) 18:328-42. 2012
    ..Leptomeningeal metastasis (LM) is an uncommon, usually late, complication of cancer. This article discusses the clinical presentation, diagnosis, prognosis, and treatment of LM...
  3. ncbi request reprint Neuroimaging: diagnosis and response assessment in glioblastoma
    Jennifer L Clarke
    Department of Neurological Surgery, Division of Neuro Oncology, University of California San Francisco, San Francisco, CA 94143 0372, USA
    Cancer J 18:26-31. 2012
    ....
  4. ncbi request reprint Pseudoprogression and pseudoresponse: challenges in brain tumor imaging
    Jennifer L Clarke
    Department of Neurological Surgery, Division of Neuro Oncology, University of California San Francisco, 400 Parnassus Avenue, A 808, Box 0372, San Francisco, CA 94143, USA
    Curr Neurol Neurosci Rep 9:241-6. 2009
    ..This article reviews the challenges of brain tumor imaging and its use in assessment of treatment response...
  5. pmc Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?
    Jennifer L Clarke
    Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Avenue, A 808, San Francisco, CA 94143 0372, USA
    Neuro Oncol 13:1118-24. 2011
    ....
  6. ncbi request reprint Recent advances in therapy for glioblastoma
    Jennifer Clarke
    Division of Neuro Oncology, Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Ave, Room A 808, Box 0372, San Francisco, CA 94143 0372, USA
    Arch Neurol 67:279-83. 2010
    ....
  7. pmc Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide
    Mei Yin C Polley
    Brain Tumor Research Center, Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, Room A 808, Box 0372, San Francisco, California 94143 2167, USA
    Neuro Oncol 12:274-82. 2010
    ..Our analysis suggests that 6-month PFS may be an appropriate primary endpoint in the context of phase II upfront GBM trials in the TMZ era...
  8. ncbi request reprint Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment
    Aaron J Clark
    Department of Neurological Surgery, University of California, San Francisco, San Francisco, California 94143 0112, USA
    Neurosurgery 70:361-70. 2012
    ..The management and prognosis of glioblastoma patients after Stupp protocol treatment and progression during bevacizumab (BV) treatment remain undefined...
  9. pmc Relationship of glioblastoma multiforme to the subventricular zone is associated with survival
    Nazia F Jafri
    Department of Radiology, University of California, San Francisco, San Francisco, California, USA
    Neuro Oncol 15:91-6. 2013
    ..003). Patients with GBM involving the SVZ have decreased overall survival and PFS, which may have prognostic and therapeutic implications...
  10. pmc Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma
    Seunggu J Han
    Department of Neurological Surgery, University of California, San Francisco, California S J H, J D R, A M M, J L C, M D P, S M C, M S B, A D, N A B Department of Epidemiology and Biostatistics, University of California, San Francisco, California A M M
    Neuro Oncol 16:1255-62. 2014
    ..A phase II trial was performed to evaluate the efficacy of a dose-dense, 7 days on/7 days off schedule of temozolomide for patients with recurrent high-grade gliomas (HGG)...
  11. ncbi request reprint Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy
    Patrick G Morris
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Thorac Oncol 7:382-5. 2012
    ..A retrospective review was carried out to assess the impact of whole brain radiotherapy (WBRT), intrathecal therapy (IT), and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) on outcomes...
  12. pmc Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma
    Jennifer L Clarke
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY10065, USA
    J Clin Oncol 27:3861-7. 2009
    ..The goal of this randomized phase II study was to evaluate two different temozolomide regimens in the adjuvant treatment of newly diagnosed GBM...
  13. pmc "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer
    Christian Grommes
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Neuro Oncol 13:1364-9. 2011
    ..Pulsatile erlotinib can control CNS metastases from EGFR mutant lung cancer after failure of standard daily dosing. CNS disease may not harbor acquired resistance mutations that develop systemically. A prospective trial is planned...
  14. ncbi request reprint Neoplastic myelopathy
    Seema Nagpal
    Division of Neuro Oncology, Department of Neurology, Stanford University, Stanford, California, USA
    Semin Neurol 32:137-45. 2012
    ..In complex cases, referral to a specialty center with access to neurosurgeons, neuroradiologists, neuropathologists, and neurooncologists is recommended...